Should Your Private Company Consider IPO in 2026?

What ASIC's Data and Fast-Track Trial Mean for Australian Businesses

The strategic landscape for Australian private companies has fundamentally shifted. While capital markets advisors once asked when will you IPO?, they now need to ask: Should you IPO at all? If so, where? And what alternatives preserve your growth without the burdens of listing?

The data is stark. ASIC records 149 IPOs on the ASX in 2014. In 2024? Just 47. That is not a market cycle, it is structural change. Australia's listed market has shrunk from 2,066 entities in 2014 to 1,910 in 2024. Private capital has become not just an alternative, but often the better choice.

This article examines what private company boards need to know about IPO options in 2026, including ASIC's regulatory response, the private capital reality, and emerging offshore alternatives.

Why IPO Activity Collapsed: The Data

ASIC's recent discussion paper on public and private markets quantifies what market participants have observed: IPO activity has declined sharply, and the listed population has contracted.

IPO windows have become shorter, more volatile, and more sensitive to pricing and aftermarket performance. But the issue is not just fewer companies going public, it is that exits through acquisition, privatisation, or failure have outpaced new entrants.

ASIC identifies multiple delisting drivers: takeovers and privatisations, liquidations and insolvencies, and voluntary delistings. While the narrative often focuses on 'IPO drought,' the delisting channel matters equally for market size.

Private Capital Is Now Structurally Competitive

This is the critical shift for private company boards: private markets are not just a bridge to IPO anymore. For many companies, they are the destination.

Drawing on ASIC's discussion paper on public and private markets, private capital competes with public markets through three key mechanisms:

1.     Valuation formation happens privately, often with lower disclosure and governance costs, meaning some companies approach IPO later or not at all

2.     Control outcomes favour private routes, trade sales or sponsor-led exits can be simpler to execute than IPO under uncertain conditions

3.     Ongoing costs tip the scales, if listing costs are perceived as high relative to marginal benefits of liquidity and follow-on funding access, staying private makes economic sense

For private companies in the $10-100M range considering their options, this is not theory. It is the strategic question: preserve optionality for IPO while capturing growth capital privately, or commit to a public path that may not deliver commensurate value?

Source: ASIC Discussion Paper, Australia's Evolving Capital Markets: A Discussion Paper on the Dynamics Between Public and Private Markets (February 2025)

ASIC's Response: The 2025 Fast-Track IPO Trial

ASIC's June 2025 fast-track trial (Media Release 25-096MR) aims to reduce execution risk by shortening timetables and minimising supplementary documentation. ASIC explicitly links this to the IPO decline identified in its public and private markets discussion paper.

What changed

1. Earlier ASIC engagement: Eligible entities can provide pathfinder prospectus confidentially 14 days before formal lodgement for informal ASIC review, potentially reducing timetable by up to a week

2. Retail applications during exposure: Class no-action position permits eligible companies to accept retail applications during exposure period

3. Eligibility constraints: Trial applies to ASX fast-track eligible entities. Under ASX Listing Rule 1.1 Condition 3, fast-track eligibility requires market capitalisation greater than $100M and no ASX-imposed escrow, among other requirements.

What This Means for Private Companies

The fast-track trial is a process change, not a reduction in legal standards. Where ASIC's enforcement intention is indicated to be  'No-action', it does not eliminate third-party risk or create a statutory safe harbor.

More importantly, the trial benefits larger, institutionally-ready floats. $20M companies contemplating IPO will not qualify. The initiative helps at the margins however does not address why most private companies choose alternatives.

What Private Companies Should Watch in 2026

Will Process Improvements Drive More IPOs?

ASIC's stated aim is reducing execution risk to deliver more IPOs. The critical question: do process improvements overcome macro conditions, valuation gaps, and aftermarket uncertainty?

In our view there is marginal improvement. Companies that were genuinely IPO-ready will benefit from faster timelines. However, companies evaluating 'IPO vs. trade sale vs. private capital' will not choose IPO because the process is three weeks shorter.

The Delisting Dynamic

ASIC emphasises that takeovers and privatisations drive delistings as much as failures do. Should the number of IPOs increase however delistings accelerate, the listed market still shrinks.

It remains to be seen whether ASX can articulate a value proposition that keeps companies listed, not just gets them there.

Offshore Listing Alternatives: The TXSE Question

Whilst ASIC works to improve ASX efficiency, Australian companies increasingly ask about offshore venues. In our view, the answer may be the Texas Stock Exchange (TXSE).

If TXSE launches as planned, it could offer Australian companies:

1. US market access without NYSE/Nasdaq listing fees

2. Potentially lower ongoing compliance burden than ASX

3. Regulatory arbitrage opportunities, that is, the ability to choose a jurisdiction with lighter regulatory requirements. In particular, if SEC Chairman Paul Atkins proceeds with his stated 'minimum effective dose' disclosure reforms, US-listed companies may face simpler ongoing compliance than ASX-listed peers.

We are watching TXSE developments closely for clients. The question is not 'will TXSE matter?', it is 'will ASX reforms arrive faster than credible offshore alternatives?' That race matters for where capital markets-ready Australian companies choose to list.

The US Regulatory Shift: A Contrasting Approach

While ASIC adds process efficiencies around the edges, the US Securities and Exchange Commission under Chairman Paul Atkins is pursuing fundamental regulatory reform. In his December 2025 speech to the New York Stock Exchange, Chairman Atkins articulated a principle:

"Capital markets thrive not through the volume of disclosures but their clarity and importance to investors. To avoid information overload, our disclosure regime is most effective when the SEC provides the minimum effective dose of regulation."

This 'minimum effective dose' philosophy represents a different regulatory direction from ASIC's approach. While ASIC's fast-track trial compresses process without reducing substance, Chairman Atkins is questioning whether the substantive burden itself has become excessive.

For Australian companies evaluating offshore listing options, this matters. If US disclosure requirements become materially lighter than Australian requirements, while still maintaining investor protection, TXSE (or other US venues) become more attractive not just for access to capital, but for lower ongoing compliance costs.

Private Markets and Superannuation Allocation

ASIC highlights superannuation funds' increasing allocation to private markets. How institutional capital flows between public and private opportunities will shape IPO depth, cornerstone support, and aftermarket liquidity.

The Strategic Questions Your Board Should Ask

The 2026 IPO landscape is not about 'yes or no' to listing. It is about preserving strategic optionality while navigating structural shifts in how capital is deployed.

For private company boards and management teams, the key questions are:

1.     Should we build IPO-ready governance and reporting even if we are unlikely to list?

2.     How do we preserve exit optionality across IPO, trade sale, private capital raise, and offshore listing?

3.     What does 'capital markets ready' mean when public listing is one of several exit paths?

Private companies should be evaluating these precise trade-offs.

How Opportuna Legal Can Assist

Opportuna Legal can assist boards, management teams and shareholders in relation to capital structure decisions, exit planning and growth funding strategies for private companies. As capital markets lawyers operating in a private capital world, we help private companies:

1. Evaluate exit pathways (trade sale, IPO, stay private, offshore listing) with capital markets sophistication

2. Structure for optionality through shareholder agreements, governance frameworks, and ownership structure management

3. Understand emerging alternatives like TXSE that other advisors may not be tracking

4. Navigate US-Australia cross-border transactions (we specialize in life sciences and defence sectors)

If you would like further information about our services or to discuss capital structure, growth funding, or exit options, please contact Opportuna Legal.

Disclaimer

This article is general information only and does not constitute legal advice. It is not intended to be relied on as a substitute for legal or other professional advice. Specific advice should be obtained for your particular circumstances.